

The future of personalised and genomic medicine - diagnosis, workforce development and early indications from the 100,000 Genomes Project

17th November 2016

CONDITIONS FOR USE OF TRANSCRIPTS:

This document is intended to provide a timely reference for interested parties who are unable to attend the event to which it refers. Some portions are based on transcripts of proceedings and others consist of text submitted by speakers or authors, and are clearly marked as such. As such, apart from where it is indicated that the text was supplied by the speaker, it has not been possible for the transcript to be checked by speakers and so this portion of the document does not represent a formal record of proceedings. Despite best endeavours by Westminster Forum Projects and its suppliers to ensure accuracy, text based on transcription may contain errors which could alter the intended meaning of any portion of the reported content. Anyone who intends to publicly use or refer to any text based on the transcript should make clear that speakers have not had the opportunity for any corrections, or check first with the speaker in question. If in doubt, please contact the forum first.

Contents

About this Publication	3
Agenda	4
Session Chair's opening remarks	
Lord Saatchi, Partner, M&C Saatchi and Chairman, Centre for Policy Studies (<i>transcript</i>)	6
Realising the potential of personalised medicine	
Professor Sue Hill, Chief Scientific Officer, NHS England (<i>transcript</i>)	8
Questions and comments from the floor (<i>transcript</i>)	12
Next steps for the 100,000 Genomes Project - translating findings into clinical practice	
Professor Mark Caulfield, Chief Scientist, Genomics England (<i>transcript</i>)	15
Collaboration between research and service delivery - the emerging role of NHS Genomic Medicine Centres	
Professor Sean Whittaker, Clinical Lead, South London NHS Genomic Medicine Centre and Co-Lead, GRIID Clinical Academic Group, King's Health Partners (<i>transcript</i>)	18
Dr Liz Mear, Chair, National AHSN Network and Chief Executive, Innovation Agency - Academic Health Science Network for the North West Coast (<i>transcript</i>)	21
Priorities for the pharmaceutical industry in the development of personalised medicine	
Dr Richard Torbett, Executive Director, Commercial UK, ABPI (<i>transcript</i>)	25
Questions and comments from the floor with Professor Sue Hill, Chief Scientific Officer, NHS England (<i>transcript</i>)	28
Session Chair's closing remarks	
Lord Saatchi, Partner, M&C Saatchi and Chairman, Centre for Policy Studies (<i>transcript</i>)	32
Session Chair's opening remarks	
Lord Turnberg, Member, Select Committee on the Long Term Sustainability of the NHS and Member, All-Party Parliamentary Group on Personalised Medicine (<i>transcript</i>)	33
Improving the prediction and diagnosis of disease - priorities for innovating and regulating diagnostics	
Doris-Ann Williams, Chief Executive, British In Vitro Diagnostics Association (<i>transcript</i>)	35
Stephen Lee, Biosciences Team Manager, MHRA and Chair, IVD Working Group, European Commission (<i>transcript</i>)	38
Questions and comments from the floor (<i>transcript</i>)	41
Key issues for implementing a personalised medicine strategy - prevention, education and patient involvement	
<i>Developing the workforce and early lessons from the Genomics Education Programme</i>	
Dr Anneke Seller, Associate Scientific Director - Genomics Education Programme, Health Education England and Director of Genetic Laboratories, Oxford University Hospitals NHS Trust (<i>transcript</i>)	44
<i>Encouraging patient engagement and participation in personalised medicine</i>	
Richard Stephens, Patient Representative, Genomics England and Consumer Lead, National Cancer Research Institute (<i>transcript</i>)	48
<i>Innovation, data and privacy - key issues for IT in genomic medicine and sequencing</i>	
Sybo Dijkstra, Senior Director, Philips Research UK (<i>transcript</i>)	51
<i>Opportunities for the third sector to contribute to research and service delivery</i>	
Professor Peter Johnson, Chief Clinician, Cancer Research UK (<i>transcript</i>)	54
<i>Ethical implications of delivering personalised and genomic medicine</i>	
Hugh Whittall, Director, Nuffield Council on Bioethics (<i>transcript</i>)	57
Questions and comments from the floor (<i>transcript</i>)	60
Keynote closing remarks	
Professor Sue Hill, Chief Scientific Officer, NHS England (<i>transcript</i>)	62
Session Chair's and Westminster Health Forum closing remarks	
Lord Turnberg, Member, Select Committee on the Long Term Sustainability of the NHS and Member, All-Party Parliamentary Group on Personalised Medicine (<i>transcript</i>)	64
Sam Dolton, Producer, Westminster Health Forum (<i>transcript</i>)	65
Comments	66
Dr Eddie Blair	
Summary: New regulations for In Vitro Diagnostics with latest timelines for implementation	
List of Delegates Registered for Seminar	68
Contributor Biographies	75
About the Core Sponsors of the Westminster Health Forum	79

Please be advised that speakers' PowerPoint presentations are included within the transcript itself, just beneath the relevant speaker's text. Please note that not all speakers are able to grant permission for us to include their slides.

About this Publication

This publication reflects proceedings at the Westminster Health Forum Keynote Seminar: The future of personalised and genomic medicine - diagnosis, workforce development and early indications from the 100,000 Genomes Project held on 17th November 2016. The views expressed in the articles are those of the named authors, not those of the Forum or the sponsors, apart from their own articles.

Although Westminster Health Forum is grateful to all sponsors for the funding on which we depend, participation in events and publications is never conditional on being a sponsor. As well as funding ongoing operations, sponsorship enables the Forum to distribute complimentary copies of publications, and offer complimentary tickets for events, to Government ministers, parliamentarians and officials most involved in policy.

This publication is copyright. Its copying, in whole or in part, is not permitted without the prior written consent of the publishers. However, extracts of the text may be reproduced for academic or review purposes, subject to the conditions of use outlined in the previous page, providing they are accurate, are not used in a misleading context and the author, their organisation and the Westminster Health Forum are acknowledged. We would also appreciate being informed.

Westminster Health Forum

UK Headquarters
4 Bracknell Beeches
Old Bracknell Lane West
Bracknell
Berkshire RG12 7BW

T: 01344 864796
F: 01344 420121
publications@westminsterforumprojects.co.uk

Directors

Peter van Gelder
Chris Whitehouse